

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 3018

Title: CMolecular Targeted Therapy for Hepatocellulararcinoma: Current and Future

Reviewer code: 00007472

Science editor: Wang, Jin-Lei

Date sent for review: 2013-04-04 17:18

Date reviewed: 2013-04-22 19:19

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Authors have written a comprehensive yet concise review of molecular targeted therapy for HCC. However, is this reviewer's opinion that the manuscript can be improved in several ways. First, recent information regarding some of the targeted agents has not always been included. For instance, the negative results of brivanib in recent studies ought to be presented and discussed. And for linifanib too even if the information we have is not more than minimal (meaningful all the same). Also, the prognostic significance of c-met over expression and details on the positive effect found for Tivantinib in c-met positive patients are worth being discussed. And the activity of IGF-targeting molecules needs to be updated. Second, too much text makes the manuscript difficult to read. The main data from clinical trials (ORR, TTP, OS, etc) could well be presented in tables so that the text is then used only for discussion. And the principal pathways and the precise site where the main agents exert its effect deserve individual figures rather than a single figure that results too simplistic. In this way, the reader would get familiar with the most relevant steps. And finally, two minor specific points. NCT numbers are lacking for a number of ongoing trials. And the major role in HCV-related carcinogenesis is probably not viral proteins but the inflammation and tissue-repair program that occurs in the cirrhotic liver